Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Study:

Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Purpose:

Phase II trial to study the effectiveness of docetaxel and gemcitabine in treating patients who have progressive regional or metastatic bladder cancer.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer
Drug: docetaxel
Drug: gemcitabine hydrochloride
Phase 2

Verified by Eastern Cooperative Oncology Group January, 2010

Sponsored by: Eastern Cooperative Oncology Group
Information provided by: Eastern Cooperative Oncology Group
ClinicalTrials.gov identifier: NCT00004223

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Robert Dreicer, MD, FACP., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site